CommercialCoverageMedium impact
Corneal Pachymetry (CPB 0681, reviewed 2025-10-15)
Aetna·Ophthalmology, Optometry·Medical Policy
Effective date
Oct 15, 2025
We identified it
Aug 15, 2026
Summary
Aetna has updated its corneal pachymetry policy (CPB 0681, effective 2025-10-15) to clarify covered indications for ultrasound corneal pachymetry and explicitly exclude coverage for refractive surgery evaluation (except in specific documented cases), artificial endothelial layer implant assessment, and screening asymptomatic patients. Billing teams must verify medical necessity documentation against the specific covered indications before submitting claims for CPT 76514.
Action Required
By October 15, 2025: Billing team must update claim submission protocols to require documented medical necessity verification for CPT 76514 (corneal pachymetry). Create a checklist in the billing system requiring claims to match one of the covered indications: anatomical narrow angles, bullous keratopathy, corneal edema, corneal refractive surgery (pre/post-op with refractive surgery plan coverage), corneal transplant (pre/post-op), complications evaluation, rejection evaluation, Fuchs' dystrophy, post-laser iridotomy status, glaucoma/glaucoma suspects (once per lifetime only), or posterior polymorphous dystrophy. Implement frequency limits: repeat testing for corneal diseases/injuries limited to once every 6 months maximum. DENY all claims for: (1) refractive surgery evaluation on plans excluding refractive surgery coverage; (2) screening asymptomatic patients without glaucoma signs/symptoms; (3) EndoART implant assessment; (4) cataract pre-op without documented corneal disease. Flag any claims with diagnoses from the non-covered list (keratoconus, Marfan syndrome, Terrien's degeneration, pterygium management, hydroxychloroquine monitoring) for automatic denial. Update encounter templates to capture specific indication and frequency of prior pachymetry tests. Consequences: Claims submitted without proper medical necessity documentation will be denied, resulting in revenue loss and potential compliance issues.